Comparison of rapid virological response in patient on treatment with Direct acting antivirals (DAA) (sofosbuvir) verses DAA along with pegylated interferon for chronic hepatitis C virus infection genotype 3

Background: hcv classified in eleven genotypes and the most common is genotype 1,2 & 3 in usa. the treatment of hepatitis c virus (hcv) infection with the available option is complicated. the rapid virologic responses may lead us to select a better treatment option in genotype 3 patients. new direct acting antiviral daa therapies for hcv infections has captured the market since last decade. hence this study aims to provide a compression of rapid virologic response over the two treatment options a) daa and b) daa plus pegylated interferon for chronic hepatitis c virus infection genotype 3. methods: this was a comparative observational study of 50 hcv infection patients with genotype 3. further divided into two groups based on treatment. rapid virologic responses were calculated against each treatment therapy. results: the rvr rate was 90% in patients with hcv genotype 3 infections who were treated for 24 weeks with daa plus peg-ifn and ribavirin (90% for noncirrhotic patients,68% for cirrhotic patients),whereas the rvr12 was 68% with the patients who were on treatment with daa drug only. conclusion: we may conclude that the treatment option b that is in a combination produced better virological rates than a,though the treatment duration is long (i.e.,upto 24 weeks).